Status:
COMPLETED
Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis
Lead Sponsor:
Kamuzu University of Health Sciences
Conditions:
Bacterial Meningitis
Eligibility:
All Genders
2-15 years
Phase:
PHASE3
Brief Summary
Bacterial meningitis remains a significant cause of morbidity and mortality in children, especially in countries with limited resources. Efforts to improve the grim outcome have included altering the ...
Detailed Description
Bacterial meningitis (BM) is a major cause of morbidity and death in the developing world. Hib and pneumococcal conjugate vaccines have the potential to prevent meningitis but neither vaccine is avail...
Eligibility Criteria
Inclusion
- All children aged ≥ 2 months, admitted to Queen Elizabeth Hospital, Blantyre, Malawi, with possible or confirmed acute bacterial meningitis
Exclusion
- Age less than two months
- Trauma
- Relevant underlying illness such as intracranial shunt, previous neurological disease (cerebral palsy, Down's syndrome)
- Previous permanent hearing loss (not conductive hearing loss) if known
- Immunosuppression except HIV infection.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
466 Patients enrolled
Trial Details
Trial ID
NCT00619203
Start Date
March 1 2008
End Date
March 1 2012
Last Update
July 10 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
College of Medicine, Queen Elizabeth Central Hospital
Blantyre, Malawi, 3